Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, we found significantly decreased expression of IL-6 in the spleen as well as decreased NF-κB in the paraventricular nucleus of rats with Yoshida ascites hepatoma.
|
31606594 |
2019 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A murine-transplanted model of the liver tumor showed that HCCs cotransplanted with HSCs could significantly enhance the tumor area and detect more MDSCs compared with HCCs alone or HCCs cotransplanted with HSCs lacking IL-6.
|
31614930 |
2019 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The protein levels of interleukin-6 (IL-6) and vascular endothelial growth factor A (VEGF-A) were persistently elevated in orthotopic liver tumors, but not in subcutaneous tumors, treated with sorafenib.
|
29266245 |
2018 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, we observed that SOCS1-deficient mice developed numerous and large liver tumor nodules following treatment with the hepatocarcinogen diethylnitrosamine (DEN) without showing increased interleukin-6 production or activation of p53.
|
26725321 |
2016 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that PML modulates IL-6-induced STAT3 activation and hepatoma cell growth by interacting with HDAC3.
|
25892518 |
2015 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In STK4-deficient mice, treatment with an IRAK1/4 inhibitor after DEN administration reduced serum IL-6 levels and liver tumor numbers to levels similar to those observed in the control mice.
|
26457732 |
2015 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activin B also induces Smad1/5/8 phosphorylation in human hepatoma-derived cells and, synergistically with IL-6 and STAT-3 signaling, up-regulates hepcidin expression markedly, an observation confirmed in mouse primary hepatocytes.
|
22611157 |
2012 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, human hepatoma cells (HuH7) were used to study the effect of IL-6 and TNF-α on HJV mRNA expression.
|
22998440 |
2012 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HBx was overexpressed in hepatic and hepatoma cell lines and IL-6 expression levels were measured by quantitative RT-PCR and ELISA.
|
20937539 |
2011 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aims of this study are to address if insulin is anti-inflammatory and attenuates IL-6-induced inflammation in the human hepatoma cell line HepG2 and if this involves signal transducer and activator of transcription 3 (STAT3) signal transduction.
|
21298325 |
2011 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of IL-6 mRNA in both hepatoma cell lines and a normal liver cell line L-02 was measured by quantitative RT-PCR.
|
22471481 |
2011 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells.
|
16054696 |
2006 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Balance of pro- and anti-inflammatory cytokines in liver surgery.
|
12940515 |
2003 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we show that a human PER1 (hPER1) reporter gene activity is stimulated by interleukin-6 (IL-6), a member of the large cytokine gene family and an inducer of the acute phase reaction, in human hepatoma (HuH-7) cells.
|
11931340 |
2002 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The induced expression of GBP28 was also observed in human hepatoma HepG2 cells after treatment with IL-6.
|
11444852 |
2001 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Peptides were tested alone or in combination with recombinant hIL-6 on an IL-6 responsive human hepatoma HepG2 cell line.
|
11405230 |
2001 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study using reverse transcriptase polymerase chain reaction (RT-PCR) we isolated and characterised a truncated form of amplified cDNA reverse-transcribed from IL-6 receptor mRNA both from human hepatoma cell line HepG2 and mononuclear cells from inflammatory bowel disease (IBD) patients.
|
10397166 |
1999 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analysed the involvement of MAPK homologues in IL-6 transduction pathways and found that interleukin-6 triggered activation of p38 stress-activated protein kinase (p38) but not of jun kinase. p38 activity was required for biological functions including acute phase protein secretion from HepG2 hepatoma and proliferation of B9 hybridoma cells.
|
10445852 |
1999 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The response of HepG2 cells to IL-6 stimulation was significantly affected by heat treatment at 40 degreesC.
|
9755236 |
1998 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study on a human hepatoma cell line and primary rat hepatocytes examined how the effectiveness of IL-6 is modified by the presence of soluble IL-6 receptor and whether the sIL-6R in the absence of IL-6 acts on hepatocytes.
|
9722935 |
1998 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report here that interleukin-6 (IL-6), the principal cytokine mediating the synthesis of most acute-phase proteins in the liver, downregulates the production of factor XII by the human hepatoma cell line HepG2 by up to 75%.
|
9269767 |
1997 |
Liver neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To study the mechanism of interleukin-6 (IL-6) induction of human C-reactive protein (CRP) gene expression, we have utilized a human hepatoma (PLC/PRF/5) cell culture system to analyze the trans-acting factors which bind to the 300 bp 5'-flanking region of human CRP gene.
|
8703909 |
1996 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The purified protein is biologically active, as determined by the ability to convert human hepatoma cells (HepG2) from nonresponsive to responsive to rat IL-6 and induce acute-phase protein synthesis.
|
8938575 |
1996 |
Liver neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We and others have previously shown that the responsiveness to IL-6 is different in hepatoma and human primary hepatocytes.
|
7545121 |
1995 |
Liver neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutagenesis of a region of human interleukin (IL)-6 which is important for triggering signal transduction via the IL-6 receptor beta-chain (gp130) has lead to the isolation of a variant of human IL-6 (IL-6.Q160E/T163P), which could antagonize the biological activity of wild type IL-6 on the human EBV transformed B cell line CESS and the human hepatoma cell line HepG2.
|
7578977 |
1995 |